BriaCell Therapeutics Corp. has announced the pricing of a public offering of 5,366,726 units, each consisting of one common share and one warrant, at a price of $5.59 per unit, raising approximately $30 million in gross proceeds. The Warrants included in the units will be listed on the Nasdaq Capital Market under the symbol “BCTXL” on January 14, 2026. The offering is expected to close on January 15, 2026, and the net proceeds will be used for working capital and advancing business objectives. ThinkEquity is the sole placement agent for the offering.

The Company is relying on an exemption from the TSX Company Manual standards for certain transactions involving eligible interlisted issuers. A registration statement on Form S-1 was filed with the SEC on December 23, 2025, and a related registration statement was filed on January 13, 2026. The final prospectus will be available from ThinkEquity in New York and on the SEC’s website. This offering is being made by prospectus and does not constitute an offer to sell or buy securities in any jurisdiction where it would be unlawful.

BriaCell Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer care. This press release contains forward-looking statements subject to risks and uncertainties. The Company undertakes no duty to update forward-looking information. Investors can contact the Company through the provided email addresses for more information.

Read more at GlobeNewswire: BriaCell Therapeutics Announces Pricing of $30 million